Neuromuscular Disorders

Therapeutic targeting of the safety factor in myasthenic syndromes 2:44
Therapeutic targeting of the safety factor in myasthenic syndromes
Hakan Cetin • 23 Jun 2021
Exciting developments in the neuromuscular field 1:52
Exciting developments in the neuromuscular field
Gabriele Siciliano • 15 Jun 2021
Research needs in seronegative myasthenia gravis 1:37
Research needs in seronegative myasthenia gravis
Hakan Cetin • 23 Jun 2021
Safety factor at the neuromuscular junction 3:17
Safety factor at the neuromuscular junction
Hakan Cetin • 23 Jun 2021
Apitegromab for the treatment of SMA 2:49
Apitegromab for the treatment of SMA
Gabriele Siciliano • 15 Jun 2021
Reduced safety factor in the pathogenesis of autoimmune and congenital myasthenic syndromes 2:37
Reduced safety factor in the pathogenesis of autoimmune and congenital myasthenic syndromes
Hakan Cetin • 23 Jun 2021
Presynaptic vs postsynaptic genetic mutations in severity of neuromuscular disease 1:24
Presynaptic vs postsynaptic genetic mutations in severity of neuromuscular disease
David Beeson • 8 Jun 2021
Collaboration between neurology and palliative care services in ALS 2:06
Collaboration between neurology and palliative care services in ALS
David Oliver • 11 Jun 2021
Robots for rehabilitation in neuromuscular disorders 3:26
Robots for rehabilitation in neuromuscular disorders
Gabriele Siciliano • 15 Jun 2021
Prevention of maternal antibody-mediated diseases 2:23
Prevention of maternal antibody-mediated diseases
Angela Vincent • 8 Jun 2021
Aspects of fetal and adult AChR function that remain unanswered 1:23
Aspects of fetal and adult AChR function that remain unanswered
David Beeson • 8 Jun 2021
Therapeutic monoclonal antibodies to prevent trans-placental transfer of pathogenic antibodies 5:46
Therapeutic monoclonal antibodies to prevent trans-placental transfer of pathogenic antibodies
Angela Vincent • 8 Jun 2021
Fetal and adult AChRs in congenital myasthenic syndromes in mice and humans 3:07
Fetal and adult AChRs in congenital myasthenic syndromes in mice and humans
David Beeson • 8 Jun 2021
Palliative care improves QoL in advanced neurodegenerative disorders 4:46
Palliative care improves QoL in advanced neurodegenerative disorders
David Oliver • 11 Jun 2021
Important considerations for the management of neuromuscular disorders 3:06
Important considerations for the management of neuromuscular disorders
Gabriele Siciliano • 15 Jun 2021
Should placebo-controlled trials be used in neuromuscular disease? 1:38
Should placebo-controlled trials be used in neuromuscular disease?
Nizar Souayah • 13 Apr 2021
The content of VJNeurology is intended for healthcare professionals